The immunizer, with messenger RNA technology, thus became the first preparation against Covid-19 approved in the bloc for children under 16.
The vaccine is tolerated' by young people, with "no major problems" detected in terms of side effects, the European regulator explained at the time.
The European Commission authorised the use of the Pfizer-BioNTech vaccine in 12- to 15-year-olds on Friday, following the European Medicines Agency's approval of administering the jabs to adolescents earlier in the day. https://t.co/KtFhQbiaes
The EMA's decision was made Friday at an extraordinary meeting of the Committee for Medicinal Products for Human Use, which concluded that the immunogen is safe and effective in adolescents.
Pfizer-BioNTech tested in Phase III clinical trials its formulation against the SARS-CoV-2 coronavirus in 2,260 adolescents and assured that its effectiveness was 100 percent, accompanied by a solid immunological response.
Since December last year, the preparation, which has been approved for use in adults last year, will be administered in two doses three weeks apart.